#IBRAA
Excellence through Innovation
TMC Fertility has been shortlisted to receive the International Business Review ASEAN Awards 2022 for Innovative Technology in the Healthcare Sector for Genetic Therapy in Fertility Treatments, in recognition of its advanced medical and technological capabilities and expertise.
Established in 1994, TMC Fertility is one of the pioneers of Malaysia’s fertility industry, offering a wide range of services such as Intra-uterine insemination (IUI), In-vitro fertilisation (IVF) and Intra-cytoplasmic sperm injection (ICSI).
CEO Irene Kwan emphasises that the team is constantly striving for excellence and innovation as it strives to make its clients’ dreams of becoming parents a reality.
Through technology such as PGT-A (preimplantation genetic testing) for the selection of the best embryos for implantation, micro-RNA to determine the best window of implantation and microfluidic sperm selection for the best selection of sperms, TMC Fertility is able to make better decisions on the best option of treatment, thus helping patients to increase their success rates.
This year, TMC Fertility has pioneered another breakthrough in fertility treatments, utilising pharmacogenomics in IVF to eliminate the guessing game in a couple’s fertility journey.
For its contributions to the fertility industry, TMC Fertility has been shortlisted to receive the International Business Review ASEAN Awards 2022.
Join us for the grand celebration this year!